MedTrace Logo

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

NCT00489840 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2012-10-25

No results posted yet for this study

Summary

Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy

Conditions

  • Chronic Central Serous Chorioretinopathy

Interventions

DRUG

Anecortave Acetate Sterile suspension 15 mg

anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months

DRUG

Anecortave Acetate

anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.

Sponsors & Collaborators

  • LuEsther T. Mertz Retinal Research Center

    collaborator OTHER

  • Alcon Research

    collaborator INDUSTRY

  • Manhattan Eye, Ear & Throat Hospital

    lead OTHER

Principal Investigators

  • Lawrence A. Yannuzzi, MD · Manhattan Eye, Ear & Throat Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489840 on ClinicalTrials.gov